NATH BIOGENES (INDIA)
Back to Balance Sheet
|
NATH BIOGENES (INDIA) Last 5 Year Total Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2013 | Mar2012 | |
---|---|---|---|---|---|
Total Liabilities | ₹880 Cr | ₹793 Cr | ₹739 Cr | ₹157 Cr | ₹119 Cr |
What is the latest Total Liabilities ratio of NATH BIOGENES (INDIA) ?
Year | Total Liabilities |
---|---|
Mar2024 | ₹880 Cr |
Mar2023 | ₹793 Cr |
Mar2022 | ₹739 Cr |
Mar2013 | ₹157 Cr |
Mar2012 | ₹119 Cr |
How is Total Liabilities of NATH BIOGENES (INDIA) Trending?
Years | Total Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹880 Cr | 11.03 | |
Mar2023 | ₹793 Cr | 7.21 | |
Mar2022 | ₹739 Cr | 369.87 | |
Mar2013 | ₹157 Cr | 32.15 | |
Mar2012 | ₹119 Cr | - |
Compare Total Liabilities of peers of NATH BIOGENES (INDIA)
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
NATH BIOGENES (INDIA) | ₹390.5 Cr | -0.2% | 6.4% | 2% | Stock Analytics | |
BOMBAY BURMAH TRADING CORPORATION | ₹13,503.0 Cr | -2.3% | -1.9% | 18.6% | Stock Analytics | |
KAVERI SEED COMPANY | ₹6,611.0 Cr | -5.3% | -5.1% | 43.9% | Stock Analytics | |
VENKYS (INDIA) | ₹2,276.8 Cr | -1.2% | -0.2% | -13% | Stock Analytics | |
BOMBAY SUPER HYBRID SEEDS | ₹1,437.8 Cr | -2% | -3.2% | -29.5% | Stock Analytics | |
INDO US BIOTECH | ₹316.3 Cr | -2.4% | 3.9% | -31% | Stock Analytics |
NATH BIOGENES (INDIA) Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NATH BIOGENES (INDIA) | -0.2% |
6.4% |
2% |
SENSEX | -1.3% |
-0.8% |
6.3% |
You may also like the below Video Courses